Although reprogramming cells to induce insulin secretion is an attractive possibility for diabetes therapy, the molecular mechanisms underlying the process of transdifferentiation of endocrine cells of the pancreatic islets into β-cells in humans have not been fully elucidated. The gene discussed is INS; the disease is diabetes mellitus.